Hints and tips:
Related Special Reports
...“We’re very much interested in a European listing”, said Juan Martinez, the head of Curaleaf International, who added that current restrictions meant “the only listing in Europe that is possible is a very...
...“If you look at how we are scaling up API capacity, we’re scaling to serve many more patients,” he said. “The more we go oral, the less we can give injectables.”...
...“[Biotech] is a very important [industry] and it’s one where the continent has an edge, but we’re not really using that edge, because we’re lacking the financial firepower the US funds have,” he said....
...GSK was fined £300mn in 2014 and dismissed more than 100 staff in China. Miels said that the pharmaceutical company has since “rebuilt” its business in China....
...They are told that their symptoms aren’t plausible, that it’s “all in their head”, that they’re too emotional, too weak, too heavy, too thin....
...“We’re well positioned to be leaders in the broader field [of radioconjugates].”...
...It is a similar milestone-based structure to many partnerships in the pharmaceutical industry....
...“CVS has put their stake in the ground that they’re going to create a marketplace where one [biosimilar] manufacturer is rewarded,” said Jon Martin, head of Organon’s US biosimilar arm, which produces Humira...
...“There was a time in that transition where the market wasn’t necessarily following where they were in their turnaround,” she said. “We’re in that moment right now.”...
...It’s a funny phrase because it makes perfect sense in the pharmaceutical context — they’re contractors who manufacture drugs and help with some of the development process — but also sounds a bit like they...
...So they didn’t anticipate correctly in the first place. And so the company has been really heavily investing in increasing supply. They’re even building like, a big plant in Denmark....
...“It was one of the most epic episodes ever in pharmaceuticals history: you got an accelerated approval of a product that didn’t have a completed phase 3 trial....
...“We’re pleased to work with Lilly to reimagine a pharmacy experience that can support better care outcomes.”...
...“We’re about 20 years behind cancer,” she said....
...But another western diplomat warned that the industry “hates transactionality . . . the idea that a country that detects a novel pathogen that has massive pandemic risk can say, ‘No, we’re not going to share...
...“We’re now in the rainy and hot season, so we can’t reverse the proliferation of the mosquito. The focus now is on care to reduce mortality.”...
...“Growth companies tend to prefer US markets, particularly in healthcare. They’re going with the flow,” he added....
...Maag said it may take longer for fundraising to rebound for the riskiest companies, but added: “If you have good clinical data and know what you’re doing, I think companies are financeable right now.”...
...“Yes we did not have a Covid vaccine, but if you look where we’re moving forward, [vaccines] are the opportunity.”...
...Novo Nordisk is under pressure to increase production of both its filled injection pens and semaglutide, the active pharmaceutical ingredient used in Ozempic and Wegovy....
...pharmaceuticals in the near future....
...We’re also reading . . ....
...I think the last box they’re still waiting for will be the point of break-even, where we turn the corner on profitability,” he said....
...Overall, consultants McKinsey estimated in a report in January that AI could generate $60bn-$110bn a year for the pharmaceutical and medical-product industries by identifying compounds for possible new drugs...
...So that’s what we’re really good at.”...
International Edition